Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:7/29/2008

SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Ronald A. Martell, president and chief operating officer, will participate in two upcoming conferences in August during which he will provide a corporate overview, including a discussion of the clinical development program and regulatory strategy for picoplatin, the Company's lead product candidate.

* Oppenheimer & Co. Inc.'s Small & Mid Cap Clinical & Regulatory Conference on Monday, August 4, at 8:40 a.m. Eastern Time at the Oppenheimer office in New York. Mr. Martell will discuss Poniard's clinical development programs and regulatory strategy, and then participate in a subsequent panel discussion, entitled "Designing A Pivotal Program with an Eye Towards Approval." During this discussion, which begins at 9:55 a.m., Mr. Martell will discuss the regulatory path to approval for picoplatin.

* BMO Capital Markets' 2008 Focus on Healthcare Conference on Tuesday, August 5, at 9:00 a.m. Eastern Time at the Millennium Broadway Hotel in New York.

A live audio webcast of each Poniard presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to e
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
2. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
3. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Announces Upcoming Conference Participation
5. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
6. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
7. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008
10. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
11. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/15/2014)... 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... a leading Russian pharmaceutical company, to develop and commercialize ... Federation , Turkey and ... a novel antibiotic for the treatment of bacterial infections ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Calif., Feb. 29 Kosan Biosciences,Incorporated (Nasdaq: ... Kosan,s,Senior Vice President and Chief Financial Officer, will ... Healthcare Conference in,New York at the W Hotel ... EST. A live,webcast of the presentation can be ...
... MannKind,Corporation (Nasdaq: MNKD ) will release its ... at 7:00 a.m. ET., Management of the Company ... financial results, clinical progress and other Company,developments at 9:00 ... the,Company will be its Chairman and Chief Executive Officer, ...
... DEERFIELD, Ill., Feb. 28 Baxter International,Inc. announced ... voluntary,recall of all remaining lots and doses of ... heparin flush products., The company initially recalled ... January 17, 2008 as a precautionary measure due ...
Cached Biology Technology:Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference 2MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on March 4, 2008 2Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products 2Baxter to Proceed With Recall of Remaining Heparin Sodium Vial Products 3
(Date:4/17/2014)... peppers. Information about archaeological remains of ancient chili peppers ... of words for chili peppers in ancient dialects helped ... the value of multi-proxy data analysis. Their results are ... presented in a special feature issue of the ... plant and animal domestication edited by Dolores Piperno, staff ...
(Date:4/17/2014)... NJ. April 16, 2014. Kessler Foundation has been ... million from the Department of Defense Spinal Cord ... principal investigator for the randomized, double-blinded, controlled, multi-site ... bone and muscle strength after spinal cord injury. ... & Engineering Research at Kessler Foundation. Two additional ...
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
Breaking Biology News(10 mins):Chickens to chili peppers 2Chickens to chili peppers 3Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2New state-of-the-art biotech and nanotech equipment for INRS 2
... few extra treats this holiday season? Soon, your cell ... exercise routine and keep the pounds off over winter ... keep track. Researchers at the University of Washington ... dubbed UbiFit and UbiGreen, to automatically track workouts and ...
... PITTSBURGHTwo groups of researchers at Carnegie Mellon University,s Robotics ... grants from the U.S. Department of Agriculture (USDA) to ... and one is for orange growers, but both are ... The systems use sensors on autonomous robotic vehicles ...
... new compounds created by a University of Central Florida ... Associate Professor James Turkson,s compounds disrupt the formation ... mice. The compounds, S3I-201 and S3I-M2001, break up ... no negative side effects so far. "The compounds ...
Cached Biology News:Track your fitness, environmental impact with new cell phone applications 2Track your fitness, environmental impact with new cell phone applications 3Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 32 new compounds show promise for eliminating breast cancer tumors 2
...
... Antibody Modification Services ,,GenScript ... antibody labeling and antibody fragmentation. Labeling ... signals for visualization and quantitation of ... it is preferable to use only ...
Attoglow Western Blot Enhancing Kit contains Millennium Enhancer which can significantly boost Western blot signals, and is compatible with other enhancing mechanisms to achieve multiplied enhancing ...
Immunogen: Synthetic peptide: S(399) P W S E L E F Q F P D D K D P V W E F(418) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: